Reliable cognitive measures for patients with Alzheimer's disease are essential when testing potential new drug interventions. The high attrition rate in Alzheimer’s disease clinical trials highlights the need for more sensitive analytical tools to be used throughout the drug development process. Global science and technology company Cambridge Cognition has made a significant advancement towards this goal; today announcing a powerful new cognitive assessment product that brings efficacy testing of Alzheimer’s treatments into the digital age.
20 May, 2015
A new study led by scientists at The Scripps Research Institute (TSRI) sheds light on the cause of some cancers, including breast cancer and leukemia.
19 May, 2015
A team led by scientists at The Scripps Research Institute (TSRI) and Johns Hopkins University School of Medicine has uncovered a big clue to how bacteria may promote some colon cancers.
08 May, 2015